BOTHELL, Wash.--(BUSINESS WIRE)--July 25, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN - News) today reported results for the second quarter ended June 30, 2006. “During the quarter, we continued to advance our diverse pipeline of clinical-stage cancer therapies,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Most notably, we reported encouraging data demonstrating clinical activity of SGN-40 in a phase I study for patients with non-Hodgkin’s lymphoma. Based on these data, we plan to advance SGN-40 into phase II clinical development in the second half of the year. In addition, we recently submitted an IND for SGN-35 to the FDA, positioning us to initiate a phase I clinical trial this year. We plan to report data from our clinical programs at the ASH annual meeting in December, which we believe will demonstrate the progress and potential of our product pipeline.”
